Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease
- PMID: 1835521
- DOI: 10.1016/0306-4522(91)90038-p
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease
Abstract
Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680). The binding of this ligand was of high affinity, reversible, and was blocked by adenosine A2 agents. Autoradiographic mapping of adenosine A2 sites revealed them to be exclusively restricted to the caudate nucleus, putamen, nucleus accumbens, olfactory tubercle and the lateral segment of the globus pallidus. The densities of adenosine A2 receptors in other brain areas did not differ from background levels. This selective localization prompted us to study the consequences of neurodegenerative diseases such as Parkinson's disease and Huntington's chorea on the densities and localization of these sites in the basal ganglia. In Parkinson's disease the density of adenosine A2 binding sites was comparable to that seen in control cases. In contrast, density values of A2 sites were dramatically decreased, compared to control values, in the basal ganglia of patients with Huntington's chorea. Similar losses of A2 receptors were observed in the guinea-pig striatum after local application of quinolinic acid while lesioning of the dopaminergic neurons was without effect. All these results taken together suggest that adenosine A2 receptors are localized on striatal output neurons which degenerate in Huntington's chorea.
Similar articles
-
Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.Synapse. 1993 Nov;15(3):209-20. doi: 10.1002/syn.890150306. Synapse. 1993. PMID: 7904088
-
The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.Neuroscience. 2000;97(3):505-19. doi: 10.1016/s0306-4522(00)00008-7. Neuroscience. 2000. PMID: 10828533
-
Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.Neuroscience. 1992 Jul;49(2):317-27. doi: 10.1016/0306-4522(92)90099-n. Neuroscience. 1992. PMID: 1436470
-
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.Curr Neuropharmacol. 2019;17(2):165-175. doi: 10.2174/1570159X16666180302115032. Curr Neuropharmacol. 2019. PMID: 29512464 Free PMC article. Review.
-
Chapter 33: the history of movement disorders.Handb Clin Neurol. 2010;95:501-46. doi: 10.1016/S0072-9752(08)02133-7. Handb Clin Neurol. 2010. PMID: 19892136 Review.
Cited by
-
Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation.Br J Pharmacol. 2012 Mar;165(6):1904-1913. doi: 10.1111/j.1476-5381.2011.01689.x. Br J Pharmacol. 2012. PMID: 21950736 Free PMC article. Clinical Trial.
-
Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.Front Neurosci. 2017 Nov 23;11:658. doi: 10.3389/fnins.2017.00658. eCollection 2017. Front Neurosci. 2017. PMID: 29217998 Free PMC article. Review.
-
Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus.J Physiol. 2001 Apr 15;532(Pt 2):423-34. doi: 10.1111/j.1469-7793.2001.0423f.x. J Physiol. 2001. PMID: 11306661 Free PMC article.
-
Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F]FLUDA by Positron Emission Tomography.Pharmaceuticals (Basel). 2022 Apr 22;15(5):516. doi: 10.3390/ph15050516. Pharmaceuticals (Basel). 2022. PMID: 35631343 Free PMC article.
-
Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.Front Neurosci. 2021 Jul 1;15:657338. doi: 10.3389/fnins.2021.657338. eCollection 2021. Front Neurosci. 2021. PMID: 34276284 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical